MANILA, Philippines — A multinational biopharmaceutical company is investing in early screening to help reduce deaths from lung cancer.
“At AstraZeneca, we are advancing our commitment to increase lung cancer screening and timely diagnosis and bring treatment to earlier lung cancer settings,” Dr. Cyril Tolosa, medical affairs director of AstraZeneca Philippines, said in an interview.
“This includes thinking differently about the underlying biology of lung cancer, from early stages – where we aim to help patients live longer and cancer-free – to late stages, where we look to meaningfully extend survival,” Tolosa added.
At the same time, the company official cited the importance of collaboration in the scientific community to improve outcomes for patients.
“AstraZeneca collaborates with key stakeholders and decision-makers to ensure innovative solutions can reach patients, no matter where they live,” she said.
“By leveraging the latest technologies and insights, AstraZeneca is dedicated to providing new options for patients and clinicians that allow them the opportunity to achieve improved survival,” she added.